Rabifin

Rabifin is a medicine used to treat gastrointestinal diseases. Let's consider who is prescribed Rabifin, its features and instructions for use.

Pharmacological group of the drug - means for the treatment and prevention of peptic ulcer, gastroesophageal reflux disease and other pathologies of the digestive organs and gastrointestinal tract. Rabifin belongs to proton pump inhibitors.

Rabifin is a proton pump drug used for the treatment and prophylactic therapy of digestive diseases. The drug is available only with a doctor's prescription.

Indications Rabifin

Rabifin is a treatment and prevention of diseases such as:

• Duodenal ulcer
• Stomach ulcer
• Gastroesophageal reflux disease
• Non-ulcer dyspepsia
• Chronic gastritis with increased acid-forming function of the stomach (in the acute stage)
• Helicobacter pуlоri eradication (with combination therapy with antibacterial agents)
• Zollinger-Ellison syndrome.

Before starting the treatment, the patient should be checked for any malignant neoplasms. This medication is not prescribed to patients with oncology. If the tablets are prescribed to patients with severe renal and hepatic dysfunction, special care should be taken in the early stages of therapy. The drug is not prescribed to pediatric patients, since there is currently no experience of its use in this age group.

[ 1 ], [ 2 ], [ 3 ], [ 4 ]

Release form

The tablet form of release simplifies the process of application, as the patient has the opportunity to calculate the necessary dosage and number of doses. The international name of the pharmaceutical product is rabeprazole.

Main physical and chemical properties: yellow tablets, round, with a gastric-soluble shell and a smooth bevel. 1 capsule may contain 10 or 20 mg of the active substance. The excipients are: magnesium oxide, microcrystalline cellulose, titanium dioxide, mannitol, hydroxypropyl methylcellulose and other components.

[ 5 ], [ 6 ]

Pharmacodynamics

Pharmacodynamics of Rabifin indicate that Rabifin belongs to the class of antisecretory compounds, i.e. to benzimidazole substitutes. The drug has no anticholinergic properties, but inhibits the secretion of gastric acid (inhibition of the enzyme H + / K + -ATPase) on the surface of the parietal cells of the stomach. This enzyme system belongs to proton, i.e. acid pumps. That is why the drug is classified as a gastric proton pump inhibitor, blocking acid at the final stage of production.

The antisecretory effect occurs an hour after administration and reaches its maximum after 2-4 hours. The effectiveness of the active substance in suppressing acid secretion increases with systematic use of the drug. But stable action is achieved 72 hours after the start of administration. After the end of use, secretory activity is restored for 2-3 days.

[ 7 ], [ 8 ], [ 9 ], [ 10 ], [ 11 ], [ 12 ], [ 13 ], [ 14 ]

Pharmacokinetics

Pharmacokinetics of Rabifin are the processes of absorption, metabolism, distribution and excretion of the drug. Let's consider each of the processes in more detail:

• Absorption – the active substance is absorbed in the intestine, the maximum concentration in the blood plasma occurs after 3-4 hours when taking a dose of 20 mg. When taken orally, bioavailability is 52% and does not increase with repeated use. Food intake does not affect absorption.
• Distribution – rabeprazole binds to blood proteins at a level of 96.3%.
• Metabolism – the main metabolites are carboxylic acid and thioether. Minor metabolites are also present in low concentrations: mercapturic acid conjugate, sulfone and dimethylthioether. The dimethyl metabolite has minor antisecretory activity, but it is not present in blood plasma.
• Excretion – 90% of the dose taken is excreted in the urine in the form of metabolites: carboxylic acid and mercapturic acid conjugate.

If the drug is used by patients with renal failure on maintenance hemodialysis, the distribution process is similar to the activity of Rabifin in healthy patients. The half-life period is from 1 to 4 hours. In this case, a doubly increased dosage was taken into account. When using tablets by patients with liver failure, the half-life period increases by 2-3 times. The half-life is about 12.3 hours.
Pharmacokinetic processes in elderly patients, that is, the processes of excretion, distribution and metabolism increase twofold. The maximum concentration in blood plasma increases by 60%, but there are no signs of accumulation.

[ 15 ], [ 16 ], [ 17 ], [ 18 ], [ 19 ], [ 20 ], [ 21 ], [ 22 ], [ 23 ], [ 24 ], [ 25 ], [ 26 ]

Dosing and administration

The method of administration and dosage are selected for each patient individually.

• Ulcer of the duodenum and peptic ulcer of the stomach - 20 mg twice a day. The course of treatment is from 2 to 4 weeks, with maintenance therapy take 10 mg once a day for up to 12 months.
• Non-ulcer dyspepsia – 20-40 mg once a day for 2-3 weeks.
• To destroy H. pуlоri – 20 mg 2 times a day for 7 days. Eradication therapy is carried out with antibiotics (amoxicillin, clarithromycin, tetracycline), metronidazole, furazolidone and bismuth preparations.
• Zollinger-Ellison syndrome - initial dose 60 mg per day and increased if necessary.
• Chronic gastritis with increased acid-forming function of the stomach (in the acute stage) – 20-40 mg per day for 2-3 weeks.

The tablets should not be chewed or crushed; the product should be swallowed whole.

[ 34 ], [ 35 ], [ 36 ], [ 37 ], [ 38 ]

Use Rabifin during pregnancy

The use of Rabifin during pregnancy is prohibited. Contraindications are based on the fact that the possibility of using tablets has not been sufficiently studied. It has been experimentally proven that the drug penetrates the placental barrier and is excreted in breast milk. Based on this, the medication is not recommended during lactation; when using it, breastfeeding should be stopped.

Given the side effect profile of the active substance, Rabifin is not recommended for use when operating machinery. The tablets may cause drowsiness and dermatological reactions.

Contraindications

Contraindications Rabifin are based on the effect of the active substance on the patient's body. Tablets are prohibited for use in the following cases:

• Individual intolerance to rabeprazole
• Hypersensitivity to benzimidazole-substituted substances or to any of the other ingredients
• During pregnancy and lactation
• Childhood of patients

The drug is used with special caution in case of renal and hepatic insufficiency. This is due to the fact that rabeprazole changes its pharmacokinetic properties.

[ 27 ], [ 28 ], [ 29 ]

Side effects Rabifin

Side effects of Rabifin occur when the instructions for its use are not followed. The pharmaceutical product is well tolerated, and the side effects are minor or moderate. Most often, patients complain of liver and digestive tract disorders: flatulence, belching, abdominal pain, diarrhea and constipation. In addition, there may be an increase in the activity of liver enzymes, dry mouth and taste disturbance.

Disturbances are possible from the side of the hematopoietic system and the nervous system: leukopenia, dizziness, drowsiness, headaches, agitation. Adverse effects are manifested in the form of allergic reactions: bronchospasm, skin rash and itching, angioedema. In rare cases, possible back and chest pain, urinary tract infections, sinusitis, pharyngitis, visual impairment, increased sweating and weight gain.

[ 30 ], [ 31 ], [ 32 ], [ 33 ]

Overdose

Overdose occurs when the recommended dosage is exceeded or when used for a long time. Most often, patients complain of symptoms such as:

• Headaches
• Dry mouth
• Nausea and vomiting
• Drowsiness
• Excessive sweating

To eliminate adverse symptoms, supportive therapy and symptomatic treatment are carried out.

[ 39 ], [ 40 ], [ 41 ], [ 42 ], [ 43 ]

Interactions with other drugs

Interaction of Rabifin with other drugs is possible with appropriate medical indications. Rabeprazole, like similar proton pump inhibitors, does not interact with drugs that are metabolized by enzymes of the CYP450 system (warfarin, phenytoin, theophylline, diazepam). The active substance causes a long-term decrease in the production of hydrochloric acid, but can work with agents whose absorption depends on the pH of the stomach contents.

Rabeprazole reduces the concentration of ketoconazole in the blood plasma by 33% and increases the minimum concentration of digoxin by 22%. Therefore, when these drugs interact, a dose adjustment is required. When used simultaneously with the active metabolite of clarithromycin, the concentration of the active component increases by 24%. The drug does not interact with liquid antacids and food.

[ 44 ], [ 45 ], [ 46 ], [ 47 ], [ 48 ], [ 49 ]

Storage conditions

Storage conditions Rabifin - tablets must be kept in the original packaging, out of reach of children and protected from sunlight. The storage temperature should not exceed 25°C.

If storage rules are not followed, the medicine loses its pharmaceutical properties and is prohibited for use.

[ 50 ], [ 51 ], [ 52 ], [ 53 ], [ 54 ]

Shelf life

The shelf life is 24 months from the date of manufacture indicated on the medicine packaging. After this period, the tablets must not be taken and must be disposed of.

[ 55 ]